Key Takeaways

• On April 1, Oklo’s leadership team—including CEO Jacob DeWitte and COO Caroline Cochran—liquidated more than $21M in company shares through pre-scheduled trading arrangements.
• DeWitte’s selling spree dates back to January, with transactions executed at prices ranging from approximately $50 to $100 per share.
• CNBC’s Jim Cramer expressed skepticism about Oklo’s commercial viability, stating the company has minimal near-term revenue potential.
• The nuclear energy startup disappointed investors with a quarterly loss of $0.27 per share, significantly worse than Wall Street’s -$0.17 forecast.
• Despite remaining nominally bullish, Wall Street analysts have trimmed their price objectives, with the current consensus target at $84.30.

Oklo’s executive leadership executed substantial stock sales totaling north of $21 million on April 1, 2026, all conducted through previously established Rule 10b5-1 trading arrangements.

Oklo Inc., OKLO

Chief Executive Jacob DeWitte liquidated shares at average prices spanning $48.41 to $51.20, generating proceeds of $10,069,852. Following these transactions, DeWitte maintains direct ownership of 691,533 Class A shares while controlling over 20 million additional shares through indirect holdings.

Co-founder and Chief Operating Officer Caroline Cochran executed similar transactions, also totaling $10,069,852, with sale prices fluctuating between approximately $47.99 and $51.79 per share. Her remaining direct stake stands at 658,039 shares.

Chief Financial Officer Richard Bealmear participated as well, selling 16,342 shares at $51.08 each for total proceeds of $834,749. His current direct holdings amount to 386,008 Class A shares.

While all three executives utilized 10b5-1 trading plans—designed to demonstrate predetermined selling schedules rather than opportunistic timing—the transactions raise eyebrows given their magnitude and timing.

DeWitte’s selling activity extends well beyond the April 1 transactions. Since January, the CEO has consistently offloaded shares at various price points, including sales near $112, $75, and $63. These cumulative transactions have generated tens of millions in personal proceeds during recent months.

The April 1 sale specifically involved 200,000 shares executed across two separate transactions, shrinking DeWitte’s direct ownership stake by 17.58%.

Cramer Questions Commercial Prospects

The executive stock sales coincide with harsh criticism from CNBC’s Jim Cramer. During a recent broadcast, Cramer delivered a blunt assessment: “Oklo, while not a science project, has very little prospects for making any money any time in the future that we think is important for a stock.”

This wasn’t Cramer’s first critique of the nuclear startup. Back in January, he characterized Oklo as lacking true commercial operations, suggesting that established players like GE Vernova represent superior investment opportunities in the nuclear sector despite Oklo’s technological promise.

Financial Performance Falls Short

The company’s operational results haven’t helped its case. Oklo disclosed a quarterly loss of $0.27 per share in its latest earnings report, substantially missing analyst expectations of a -$0.17 loss—a negative variance of $0.10 per share.

Despite this disappointment, Wall Street analysts haven’t abandoned the stock entirely, though enthusiasm has clearly cooled. UBS slashed its price target from $95 down to $60 while adopting a neutral stance. Needham made an even steeper cut from $135 to $73, and Canaccord reduced its target from $175 to $125. Cantor Fitzgerald maintained an overweight recommendation with a $122 price objective.

The analyst community’s average price target currently registers at $84.30, accompanied by a “Moderate Buy” consensus rating. The breakdown includes two Strong Buy recommendations, nine Buy ratings, six Hold positions, and two Sell ratings.

Oklo’s shares have experienced significant volatility over the past year, trading within a 12-month range of $17.42 to $193.84. The stock’s 50-day moving average currently sits at $64.62, well below its 200-day moving average of $93.16.